During a Case-Based Roundtable® event, Vamsidhar Velcheti, MD, discussed the TRIDENT-1 trial and practical considerations for ...

Learn how new research and clinical trials at Memorial Sloan Kettering Cancer Center (MSK) have helped 32-year-old Giancarlo ...

Panelists discuss treatment decision-making for metastatic non–-small cell lung cancer (NSCLC) with a ROS1 alteration, ...

The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in ...

Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today reported financial results for the fourth quarter and full year ended ...

Currently there is a lack of treatments for ROS1-positive NSCLC, especially for people whose lung cancer has spread to the brain. Factoring the discount, Rozlytrek costs up to £42,500 per QALY ...

positive lung cancer (ROS1)-positive NSCLC According to research, about 50% to 60% of people with EGFR- or ALK-positive lung cancer go on to develop brain mets. Why is this? Doctors aren’t sure.